Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EPS (Weighted Average and Diluted) (2018 - 2026)

Tandem Diabetes Care filings provide 8 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.01 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 200.0% to -$0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.07, a 110.27% decrease, with the full-year FY2025 number at -$3.04, down 106.8% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Tandem Diabetes Care, up from -$0.31 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.16 in Q4 2021 to a low of -$1.97 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.33 (2025), compared with a mean of -$0.46.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 160.0% in 2021 and later crashed 944.44% in 2022.
  • Tandem Diabetes Care's EPS (Weighted Average and Diluted) stood at $0.16 in 2021, then tumbled by 256.25% to -$0.25 in 2022, then crashed by 84.0% to -$0.46 in 2023, then skyrocketed by 102.17% to $0.01 in 2024, then tumbled by 200.0% to -$0.01 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.01 (Q4 2025), -$0.31 (Q3 2025), and -$0.78 (Q2 2025) per Business Quant data.